Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suglat in T2DM and NAFLD
NCT02875821Phase 4Completed
- Sponsor
- Yonsei University
- Start
- Apr 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ipragliflozin in non-alcoholic fatty liver disease (NAFLD), sponsored by Yonsei University. Started Apr 2016; status: completed.
02
Drugs
ipragliflozin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02875821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02875821.